Who is sponsoring NCT03859128?

NCT03859128 is sponsored by Shanghai Junshi Bioscience Co., Ltd..

What drugs are being tested in NCT03859128?

Interventions in NCT03859128: TORIPALIMAB INJECTION(JS001 ).

What condition does NCT03859128 study?

NCT03859128 studies Hepatocellular Carcinoma.

Is NCT03859128 still recruiting?

NCT03859128 is currently status unknown. Last updated 31 March 2023.

Last reviewed 2023-03-31 · How we verify

NCT03859128: JUPITER 04

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Status unknown Phase 2, PHASE3 Last updated 31 March 2023

What this trial tests

Phase 2, PHASE3 trial testing TORIPALIMAB INJECTION(JS001 ) in Hepatocellular Carcinoma in 402 participants. Status unknown.

Timeline

5 March 2019

Primary endpoint
18 April 2023

1 August 2023

Quick facts

Lead sponsor	Shanghai Junshi Bioscience Co., Ltd.
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	402
Start date	5 March 2019
Primary completion	18 April 2023
Estimated completion	1 August 2023
Sites	1 location across China

Drugs / interventions tested

TORIPALIMAB INJECTION(JS001 ) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Shanghai Junshi Bioscience Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual of tumour.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Therapies for Hepatocellular Carcinoma (HCC).
Chakraborty E, Sarkar D. · · 2022 · cited 236× · PMID 35681776 · DOI 10.3390/cancers14112798
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
Giraud J, Chalopin D, Blanc JF, Saleh M. · · 2021 · cited 172× · PMID 33815418 · DOI 10.3389/fimmu.2021.655697
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
Luo XY, Wu KM, He XX. · · 2021 · cited 144× · PMID 34006331 · DOI 10.1186/s13046-021-01968-w
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights.
Xie DY, Zhu K, Ren ZG, Zhou J, et al · · 2023 · cited 117× · PMID 37124695 · DOI 10.21037/hbsn-22-469
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].
Department of Medical Administration, National Health and Health Commission of the People's Republic of China. · · 2020 · cited 116× · PMID 32164061 · DOI 10.3760/cma.j.issn.1007-3418.2020.02.004
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
Immune Checkpoint Inhibitors in the Treatment of HCC.
Donisi C, Puzzoni M, Ziranu P, Lai E, et al · · 2020 · cited 105× · PMID 33585218 · DOI 10.3389/fonc.2020.601240
Liver Cancer Immunity.
Ilyas SI, Wang J, El-Khoueiry AB. · · 2021 · cited 81× · PMID 32516437 · DOI 10.1002/hep.31416

Verify or expand the search:

Other trials of TORIPALIMAB INJECTION(JS001 )

Trials testing the same drug.

NCT06919848 — Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tr · Phase 2 · not yet recruiting
NCT06903871 — Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Comp · Phase 2 · not yet recruiting
NCT06705127 — Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. · Phase 2 · recruiting
NCT03924050 — Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI · Phase 3 · unknown
NCT06889649 — SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC · Phase 2 · recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Shanghai Junshi Bioscience Co., Ltd. trials

Trials by the same sponsor.

NCT07503756 — JS212 Combination Therapies in Metastatic Colorectal Cancer · Phase 2 · not yet recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07484724 — A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Ce · Phase 2 · not yet recruiting
NCT07518160 — JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study · Phase 2 · not yet recruiting
NCT07309276 — A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03859128 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Junshi Bioscience Co., Ltd.
Last refreshed: 31 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03859128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing